SCHEMBL15068058

SCHEMBL15068058

CC(C)(C)OC(=O)CN1CCOCCOCCN(CC(=O)OC(C)(C)C)CCOCCOCC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
USP2 O75604 1/20 0.56
HSD17B10 Q99714 2/20 0.53
KDM4E B2RXH2 3/20 0.52
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
RECQL P46063 2/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
EGFR P00533 1/20 0.40
ALDH1A1 P00352 5/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12014405 0.98 SMN1; SMN2 (0.53) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL25404852 0.96 SMN1; SMN2 (0.51) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL28864679 0.92 SMN1; SMN2 (0.47) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL26270891 0.90 HSD17B10 (0.61) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL25148143 0.89 SMN1; SMN2 (0.45) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL26270895 0.85 SMN1; SMN2 (0.42) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL28292220 0.85 KDM4E (0.49) SMN1; SMN2USP2HSD17B10KDM4ETSHR
SCHEMBL3470166 0.85 PLA2G10 (0.41) SMN1; SMN2USP2KDM4ETSHRMEN1
SCHEMBL3799622 0.85 PLA2G10 (0.41) SMN1; SMN2USP2KDM4ETSHRMEN1
SCHEMBL27147241 0.85 PLA2G10 (0.41) SMN1; SMN2USP2KDM4ETSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797900-B1 COMPLEX-FORMING COMPOUNDS STRATOXER S KFT (HU) 2016-09-28 EP disclosed
US-9243031-B2 Complex-forming compounds STRATOXER(S) KFT. (HU) 2016-01-26 US disclosed
US-9243031-B2 Complex-forming compounds STRATOXER(S) KFT. (HU) 2016-01-26 US disclosed
US-9243031-B2 Complex-forming compounds STRATOXER(S) KFT. (HU) 2016-01-26 US disclosed
US-20140342997-A1 COMPLEX-FORMING COMPOUNDS STRATOXER(S) KFT. (HU) 2014-11-20 US disclosed
US-20140342997-A1 COMPLEX-FORMING COMPOUNDS STRATOXER(S) KFT. (HU) 2014-11-20 US disclosed
US-20140342997-A1 COMPLEX-FORMING COMPOUNDS STRATOXER(S) KFT. (HU) 2014-11-20 US disclosed
EP-2797900-A1 COMPLEX-FORMING COMPOUNDS Stratoxer(S) Kft. (HU) 2014-11-05 EP disclosed
WO-2013098572-A1 COMPLEX-FORMING COMPOUNDS STRATOXER(S) KFT. (HU) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140342997-A1 COMPLEX-FORMING COMPOUNDS F2, CYP2F1, CYP4F2 SMN1; SMN2 3136/4885USP2 4599/4885HSD17B10 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.